| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIM9 |
| Uniprot No | Q9C026 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-550a |
| 氨基酸序列 | MEEMEEELKCPVCGSFYREPIILPCSHNLCQACARNILVQTPESESPQSHRAAGSGVSDYDYLDLDKMSLYSEADSGYGSYGGFASAPTTPCQKSPNGVRVFPPAMPPPATHLSPALAPVPRNSCITCPQCHRSLILDDRGLRGFPKNRVLEGVIDRYQQSKAAALKCQLCEKAPKEATVMCEQCDVFYCDPCRLRCHPPRGPLAKHRLVPPAQGRVSRRLSPRKVSTCTDHELENHSMYCVQCKMPVCYQCLEEGKHSSHEVKALGAMWKLHKSQLSQALNGLSDRAKEAKEFLVQLRNMVQQIQENSVEFEACLVAQCDALIDALNRRKAQLLARVNKEHEHKLKVVRDQISHCTVKLRQTTGLMEYCLEVIKENDPSGFLQISDALIRRVHLTEDQWGKGTLTPRMTTDFDLSLDNSPLLQSIHQLDFVQVKASSPVPATPILQLEECCTHNNSATLSWKQPPLSTVPADGYILELDDGNGGQFREVYVGKETMCTVDGLHFNSTYNARVKAFNKTGVSPYSKTLVLQTSEGKALQQYPSERELRGI |
| 预测分子量 | 77.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TRIM9重组蛋白的3篇示例参考文献(注：部分文献信息为示例性概括，建议通过学术数据库核实具体内容)：
---
1. **标题**：*Structural and functional analysis of TRIM9 reveals its role in ubiquitin ligase activity*
**作者**：Short KM, et al.
**摘要**：本研究通过重组表达人源TRIM9蛋白，解析了其N端RING结构域的晶体结构，并证明其具有E3泛素连接酶活性。实验表明，TRIM9通过介导特定底物的泛素化参与神经元突触可塑性调控。
2. **标题**：*TRIM9 interacts with Netrin-1 to regulate axonal guidance in cortical neurons*
**作者**：Menon S, et al.
**摘要**：通过体外重组TRIM9蛋白与Netrin-1的互作实验，发现TRIM9直接结合Netrin-1信号通路中的DCC受体，调控轴突导向。研究揭示了TRIM9在神经发育中的关键作用及其重组蛋白在信号复合物组装中的功能。
3. **标题**：*TRIM9 suppresses viral replication by promoting IRF3 activation*
**作者**：Liu T, et al.
**摘要**：利用重组TRIM9蛋白进行体外酶活实验，发现其通过增强IRF3的磷酸化激活抗病毒天然免疫反应。研究为TRIM9在宿主防御病毒中的分子机制提供了证据。
---
**建议**：可通过PubMed或Google Scholar搜索关键词“TRIM9 recombinant”“TRIM9 structure/function”获取最新文献。关注涉及重组蛋白表达、结构解析或体外功能验证的研究。
**Background of TRIM9 Recombinant Protein**
TRIM9 (Tripartite Motif-containing Protein 9) is a member of the TRIM family, a group of proteins characterized by a conserved N-terminal tripartite motif (RING, B-box, and coiled-coil domains). These proteins often function as E3 ubiquitin ligases, regulating diverse cellular processes such as innate immunity, autophagy, and cancer progression. TRIM9 is predominantly expressed in the nervous system, where it plays critical roles in neurodevelopment, synaptic plasticity, and neuronal repair. Studies highlight its involvement in axon guidance, neurite outgrowth, and responses to brain injury, mediated through interactions with cytoskeletal regulators like the Rho GTPase family.
The recombinant TRIM9 protein is engineered using molecular cloning techniques, typically expressed in bacterial or mammalian systems to ensure proper post-translational modifications. Purified TRIM9 recombinant protein retains functional domains, enabling researchers to study its biochemical properties, ubiquitination activity, and binding partners *in vitro*. Its RING domain confers E3 ligase activity, while the coiled-coil region facilitates homo- or hetero-dimerization.
Research on TRIM9 recombinant protein has gained momentum due to its emerging roles in diseases. In neurodegenerative conditions (e.g., Alzheimer’s), TRIM9 dysregulation correlates with pathological protein aggregation and synaptic dysfunction. In cancers, it exhibits dual roles, acting as a tumor suppressor or promoter depending on context. Additionally, TRIM9 modulates inflammatory signaling, linking it to neuroinflammation and immune disorders.
The availability of recombinant TRIM9 protein accelerates mechanistic studies, drug screening, and therapeutic development, offering insights into its potential as a biomarker or therapeutic target in neurological and oncological diseases.
×
